-47%

est. 2Y upside i

HealthcareSeries D+

We automate operations for hospitals and health systems

Rank

#3231

Sector

Healthcare Technology

Est. Liquidity

~3Y

Data Quality

Data: Medium

Despite 40% YoY growth and a strong moat, the expected 2-year return for common equity is -47%.

Last updated: July 3, 2026

Bull (15%)+19%

IPO window opens and multiple expands to 10x forward revenue on $55.5M projected revenue, giving $555M exit. Common sees +38.8% before 20% dilution, net +18.8%.

Base (55%)-37%

Multiple contracts to 6x, inline with comps, valuing the company at $333M. Combined with 20% dilution, common equity declines ~36.7%.

Bear (30%)-100%

Exit value below $201M preference stack; common stock recovers nothing. Multiple compression to 2x or lower due to incumbent pressure.

Est. time to liquidity~2.5 years

Preference Stack Risk

severe

Funding Intensity

5025%

Total funding $201M represents 50.25% of current $400M valuation, creating a high preference overhang.

Dilution Risk

moderate

Recent Series D may extend runway, but high burn could require further dilution before liquidity event.

Secondary Liquidity

none

No active secondary market observed; secondary implied value nearly identical to primary round.

Questions to Ask at the Interview

Strategic questions based on Qventus's data — designed to show you've done your homework.

  • 1

    “How does Qventus sustain competitive advantage against Epic's native OR Marketplace?”

  • 2

    “What are the key unit economics and path to profitability?”

  • 3

    “Given the preference stack, how do you evaluate the risk/reward of early common equity?”

Community

Valuation Sentiment

Our model estimates -47% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.